While the idea of administering a shot may seem intimidating, the process is simple, safe, and designed for ease
6 Mechanistically that follows: bulking and viscous fibres slow gastric emptying, and a GLP-1 is already slowing it
Depress the plunger slowly, letting the water run down the inside wall of the vial and onto the powder gently
What the evidence supports: Injectable semaglutide was undetectable in breast milk from eight nursing mothers at doses up to 1 mg weekly Injectable tirzepatide was undetectable in approximately 96 percent of milk samples from 11 nursing mothers at 5 mg doses Both medications have molecular weights (4,114 and 4,813 Daltons) that make significant milk transfer biologically unlikely Any trace amounts in milk would have negligible oral bioavailability in the infant No adverse infant effects were observed in any of the lactation studies LactMed states tirzepatide is not a reason to discontinue breastfeeding What the evidence does not support: Use of oral semaglutide (Rybelsus) during breastfeeding due to the absorption enhancer SNAC Use of any GLP-1 agonist without physician supervision during lactation Aggressive weight loss goals (more than 1 to 1.5 pounds per week) while breastfeeding Assumption that compounded formulations carry the same safety profile as pharmaceutical-grade products without specific data What remains unknown: Safety at higher therapeutic doses (semaglutide above 1 mg, tirzepatide above 5 mg) Long-term infant outcomes from maternal GLP-1 exposure during breastfeeding Effects on breast milk composition and nutritional quality Safety of newer GLP-1 agonists like retatrutide The decision is ultimately yours and your physician's
Future Candidates for Retatrutide Once it successfully clears regulatory hurdles, retatrutide may become preferred for: Individuals with severe obesity who have plateaued on dual-agonist or mono-agonist therapies
LinkedIn: @jamy_ard
%201600x800.webp)
